-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 6, Ganli Pharmaceutical issued an announcement stating that it had recently received an official written reply from the European Commission ("EC"), granting the company's innovative drug cyclin-dependent kinase 4/6 (CDK4/6) inhibition (Hereinafter referred to as "GLR2007") orphan drug qualification certification for the treatment of glioma.
GLR2007 is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
This time, Ganli Pharmaceutical's innovative drug GLR2007 was successfully approved by the European Commission (EC) as an orphan drug for the treatment of glioma.
As of September 30, 2020, the GLR2007 project has invested a total of 57.